Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: Quantitative extrapolation to humans

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 39, Issue 5, 2012, Pages 463-477

  Stevens, Jasper ^a   Ploeger, Bart A ^b   Hammarlund Udenaes, Margareta ^c   Osswald, Gunilla ^d   Van Der Graaf, Piet H ^e   Danhof, Meindert ^a,b   De Lange, Elizabeth C M ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LAPandP Consultants BV   (Netherlands)

^c UPPSALA UNIVERSITY   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

PK PD model; Prolactin; Remoxipride; Translational

Indexed keywords

DOPAMINE; PROLACTIN; REMOXIPRIDE;

ALLOMETRY; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXTERNAL VALIDITY; EXTRACELLULAR FLUID; HOMEOSTASIS; HORMONE INHIBITION; HUMAN; MALE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; NEGATIVE FEEDBACK; NONHUMAN; OUTCOME ASSESSMENT; PHARMACOKINETIC PHARMACODYNAMIC MODEL; POSITIVE FEEDBACK; PREDICTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROCESS MODEL; PROLACTIN RELEASE; PROLACTIN SECRETING CELL; PROLACTIN SYNTHESIS; QUANTITATIVE ANALYSIS; RAT;

ANIMALS; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DOPAMINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MODELS, BIOLOGICAL; PROLACTIN; RANDOM ALLOCATION; RATS; RATS, WISTAR; REMOXIPRIDE;

EID: 84870441696     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-012-9262-4     Document Type: Article

References (39)

1. Petty RG (1999) Prolactin and antipsychotic medications: mechanism of action. Schizophr Res 35(Suppl):S67-S73
2. Movin-Osswald G, Hammarlund-Udenaes M (1995) Prolactin release after remoxipride by an integrated pharmacokinetic- pharmacodynamic model with intra- and interindividual aspects. J Pharmacol Exp Ther 274:921-927
3. Freeman ME, Kanyicska B, Lerant A, Nagy G (2000) Prolactin: structure, function, and regulation of secretion. Physiol Rev 80:1523-1631
4. Bagli M, Suverkrup R, Quadflieg R, Hoflich G, Kasper S, Moller HJ, Langer M, Barlage U, Rao ML (1999) Pharmacokinetic- pharmacodynamic modeling of tolerance to the prolactin-secreting effect of chlorprothixene after different modes of drug administration. J Pharmacol Exp Ther 291:547-554
5. Friberg LE, Vermeulen AM, Petersson KJF, Karlsson MO (2008) An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment. Clin Pharmacol Ther 85:409-417
6. Ma G, Friberg LE, Movin-Osswald G, Karlsson MO (2010) Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin. Br J Clin Pharmacol 70:815-824
7. Danhof M, De Jongh J, De Lange EC, Della PO, Ploeger BA, Voskuyl RA (2007) Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 47:357-400
8. Ploeger BA, Van der Graaf PH, Danhof M (2009) Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling. Drug Metab Pharmacokinet 24:3-15
9. Gabrielsson J, Green AR (2009) Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology. J Pharmacol Exp Ther 331:767-774
10. Danhof M, De Lange EC, Della Pasqua OE, Ploeger BA, Voskuyl RA (2008) Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci 29:186-191
11. De Lange EC, De Boer AG, Breimer DD (2000) Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv Drug Deliv Rev 45:125-148
12. Yassen A, Olofsen E, Kan J, Dahan A, Danhof M (2007) Animalto- human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine. Clin Pharmacokinet 46:433-447
13. Zuideveld KP, Van der Graaf PH, Peletier LA, Danhof M (2007) Allometric scaling of pharmacodynamic responses: application to 5-ht1a receptor mediated responses from rat to man. Pharm Res 24:2031-2039
14. Boxenbaum H (1982) Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201-227
15. Stevens J, Ploeger BA, Van der Graaf PH, Danhof M, De Lange EC (2011) Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration. Drug Metab Dispos 39:2275-2282
16. Stevens J, Suidgeest E, Van der Graaf PH, Danhof M, De Lange EC (2009) A new minimal-stress freely-moving rat model for preclinical studies on intranasal administration of CNS drugs. Pharm Res 26:1911-1917
17. Stevens J, Van den Berg D-J, De Ridder S, Niederlander HAG, Van der Graaf PH, Danhof M, De Lange ECM (2010) Online solid phase extraction with liquid chromatography-tandem mass spectrometry to analyze remoxipride in small plasma-, brain homogenate-, and brain microdialysate samples. J Chromatogr B 878:969-975
18. Gisleskog PO, Karlsson MO, Beal SL (2002) Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn 29:473-505
19. Mohell N, Sallemark M, Rosqvist S, Malmberg A, Hogberg T, Jackson DM (1993) Binding characteristics of remoxipride and its metabolites to dopamine d2 and d3 receptors. Eur J Pharmacol 238:121-125
20. Chi HJ, Shin SH (1978) The effect of exposure to ether on prolactin secretion and the half-life of endogenous prolactin in normal and castrated male rats. Neuroendocrinology 26:193-201
21. Post TM, Freijer JI, Ploeger BA, Danhof M (2008) Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn 35:185-202
22. Abelo A, Eriksson UG, Karlsson MO, Larsson H, Gabrielsson J (2000) A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog. J Pharmacol Exp Ther 295:662-669
23. Ben Jonathan N, LaPensee CR, LaPensee EW (2008) What can we learn from rodents about prolactin in humans? Endocr Rev 29:1-41
24. Phelps CJ (1986) Immunocytochemical analysis of prolactin cells in the adult rat adenohypophysis: distribution and quantitation relative to sex and strain. Am J Anat 176:233-242
25. Dada MO, Campbell GT, Blake CA (1984) Pars distalis cell quantification in normal adult male and female rats. J Endocrinol 101:87-94
26. Asa SL, Penz G, Kovacs K, Ezrin C (1982) Prolactin cells in the human pituitary. A quantitative immunocytochemical analysis. Arch Pathol Lab Med 106:360-363
27. Utama FE, Tran TH, Ryder A, LeBaron MJ, Parlow AF, Rui H (2009) Insensitivity of human prolactin receptors to nonhuman prolactins: relevance for experimental modeling of prolactin receptor-expressing human cells. Endocrinology 150:1782-1790
28. Kohler C, Radesater AC, Karlsson-Boethius G, Bryske B, Widman M (1992) Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipride. A biochemical and autoradiographic analysis in the rat brain. J Neural Transm Gen Sect 87:49-62
29. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78:189-225
30. Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR (2005) Intrinsic efficacy of antipsychotics at human d2, d3, and d4 dopamine receptors: identification of the clozapine metabolite n-desmethylclozapine as a d2/d3 partial agonist. J Pharmacol Exp Ther 315:1278-1287
31. Perello M, Chacon F, Cardinali DP, Esquifino AI, Spinedi E (2006) Effect of social isolation on 24-h pattern of stress hormones and leptin in rats. Life Sci 78:1857-1862
32. Featherstone K, White MR, Davis JR (2012) The prolactin gene: a paradigm of tissue-specific gene regulation with complex temporal transcription dynamics. J Neuroendocrinol 24:977-990
33. Widman M, Nilsson LB, Bryske B, Lundstrom J (1993) Disposition of remoxipride in different species. Species differences in metabolism. Arzneimittelforschung 43:287-297
34. Farde L, Von Bahr C (1990) Distribution of remoxipride to the human brain and central d2-dopamine receptor binding examined in vivo by pet. Acta Psychiatr Scand Suppl 358:67-71
35. Al-Fulaij MA, Ren Y, Beinborn M, Kopin AS (2007) Identification of amino acid determinants of dopamine 2 receptor synthetic agonist function. J Pharmacol Exp Ther 321:298-307
36. Karabulut AK, Pratten MK (1998) Species-specificity of growthpromoting effects of prolactin during rat embryogenesis. J Anat 192(Pt 1):1-12
37. Van der Graaf PH, Van Schaick EA, Math-ot RA, Ijzerman AP, Danhof M (1997) Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors. J Pharmacol Exp Ther 283:809-816
38. Visser SA, Wolters FL, Gubbens-Stibbe JM, Tukker E, Van der Graaf PH, Peletier LA, Danhof M (2003) Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: in vitro-in vivo correlations. J Pharmacol Exp Ther 304:88-101
39. Zuideveld KP, Van der Graaf PH, Newgreen D, Thurlow R, Petty N, Jordan P, Peletier LA, Danhof M (2004) Mechanism-based pharmacokinetic-pharmacodynamic modeling of 5-ht1a receptor agonists: estimation of in vivo affinity and intrinsic efficacy on body temperature in rats. J Pharmacol Exp Ther 308:1012-1020